Logo Loading...

Phone: +91 7499180452

Immunomodulators Market by Size, Share, Types (Immunosuppressants, Immunostimulants), Applications (Oncology, Respiratory, HIV) and Forecasts by 2027

Global 55 market was valued at around USD 166.07 billion in 2020 and is expected to grow with the CAGR of 5.10% during forecast period 2021-2027.

Market Overview:

Immunomodulators are natural or synthetic substances that modify or modulates the immune response. They help regulate or normalize the immune system by either stimulating or suppressing the immune system. Immunostimulants, such as interferons and vaccines, enhance the body’s resistance against infections. Immunomodulators generally classified into two categories: immunosuppressants and immunostimulants. Within each category, there are several types of medications, each with unique mechanisms of action, indications (both labeled and unlabeled), and with unique immune targets. The number of medications used to manage autoimmune disorders has increased dramatically in the recent years. The immunomodulators have resulted in improvements in patient outcomes by slowing of disease progression. Each type of immunomodulator medication contains a particular kind of active ingredient that acts and works by changing the way that the immune system carries out its functions in a specific person’s body. Some of these drugs work by suppressing or weakening the immune system, and others by modifying the way it works in different ways. Immunosuppressant drugs are used to decrease the immune response by interfering with the function or production of cytokines and immune cells.

Immunomodulators are widely used in chronic illness and recommended for people with autoimmune diseases, as they help to restore immune system health in people who have been on lengthy courses of antibiotics or anti-viral therapies. There are ongoing trends of immunomodulation to combat a vast range of animal and human diseases including the incurable diseases like cancers, autoimmune diseases, viral diseases, and inflammatory conditions. Immunomodulators are most commonly used to treat patients with autoimmune disorders that is severe or moderate. The majority of new immunomodulators in development, which is likely to provide more growth opportunities in the market. Major players such as GSK and Pfizer are focusing on the development of new drugs.

Market Dynamics:

Drivers:

  • Rising incidences of  multiple sclerosis propelling the market growth

In multiple sclerosis (MS), the immune system attacks nerve cells, causing symptoms that can include weakness, poor coordination, muscle spasms, pain, and blindness. It is one of the most common disorder and poses a major personal and socioeconomic burden. For instance, as per the study by National Society of MS, currently, an estimated 2.3 million people live with multiple sclerosis worldwide. Immunomodulators are used for the treatment of relapsing forms of multiple sclerosis. Thus, rising incidences of multiple sclerosis is propelling the market growth.

 

  • Increasing adoption of immunomodulator therapy for the treatment of Crohn's disease

Immunomodulator is an effective treatment for the people with Crohn's disease. It can be used either single in pair with other medications. These drugs helps to modify or weaken the immune system to reduce inflammation caused by Crohn’s disease, which can help to reduce symptoms and keep the patients in remission. Thus, increasing adoption of immunomodulator therapy for the treatment of Crohn's disease, driving the growth of market.  

Restraints:

  • Adverse side effects of immunomodulator drugs

One of the greatest risk for patients receiving immunomodulators is the concern of infection, both primary infection and reactivation of latent infections. Problems include latent tuberculosis (TB), reactivation of hepatitis B and hepatitis C viruses, herpesviruses, HIV, invasive fungal infections, Pneumocystis jiroveci pneumonia (PJP), and progressive multifocal leukoencephalopathy (PML). Thus, prior to initiation of immunomodulator treatment, patients must be screened for risk factors or historical exposure to the pathogens associated with these infections.

Opportunities:

  • Increasing R&D activities will provide future growth opportunities

The increasing interest in immunomodulators leads to the discovery and development of diverse array of new drugs and treatment for the various autoimmune disorders. Many key vendors are investing heavily in the research and development activities and focusing on the launching the new drugs to cater the demand of large number of customers. A number of disorders such as immunodeficiency state, autoimmune disease, cancer and viral infection can be treated with immunostimulants drugs. Thus, with the widening scope of immunomodulators to treat large number of diseases, offering potential opportunities for the key vendors in the market.

Challenges:

  • Stringent government regulations for the approval and launch of the drug

Stringent government regulations for the approval and launch of the immunomodulators drug is one of the key challenge for the vendors.  For the approval of the drugs, drug manufacturers must conduct lab, animal, and human clinical testing and submit their data to the respective regulatory institutes to verify the safety and efficacy of the drug. This procedure takes lot of time and requires heavy capital investment. Thus, these factors is anticipated to hinder the market growth over the forecast period.

Segmentation Analysis:

The global immunomodulators market has been segmented based on type, route of administration, application, and regions.

  • The type segment is divided into immunosuppressants and immunostimulants. The immunosuppressants segment further classified into calcineurin inhibitors, antimetabolites, glucocorticoids, and others. Immunostimulants further divided into vaccines, antibodies, others. Immunosuppressants segment led the immunomodulators market with the highest market share and valued at USD 88.76 billion in 2019. This is mainly attributed to presence of wide product range in this segment with the ability to treat the variety of autoimmune diseases. These drugs suppress or reduce, the strength of the body's immune system. These drugs are given for autoimmune disorders such as multiple sclerosis (MS), Rheumatoid arthritis, alopecia areata, and lupus, to decrease the undesirable immune response of the body.
  • The route of administration segment includes oral, injectable, and intravenous. The oral route of administration is estimated to grow at the highest CAGR of 6.9% over the forecast period, as it is one of the most convenient and usually the safest and least expensive route of administration. After oral administration, these drugs quickly absorbed and approximately 30% circulate in the blood bound to plasma proteins. Drugs in the form of liquids, capsules, tablets, or chewable tablets, can be taken orally.
  • The application segment includes respiratory, human immunodeficiency virus (HIV), oncology, and others. Other segment includes disease such as multiple sclerosis, Crohn's disease, rheumatoid arthritis, etc. Other segment accounted for the major market share of 45.6% in 2019. This is mainly due to wide used of immunomodulators for the treatment of these diseases. These drugs have been used for over two decades to treat relapsing these diseases. Imunomodulators help to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.

Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa. The North America region emerged as the largest market for the immunomodulators market with a 38.7% share of the market revenue in 2019.

  • This is because North America has the highest number of population suffering from the autoimmune diseases. In addition to this, presence of large number of companies in the region, positively impacting the growth of market. For instance, as per the study of National institute of Environmental Science, autoimmune diseases affect more than 24 million people in the United States. In addition to this, as per the National Multiple Sclerosis Society, Canada is the country, which has the highest prevalence of multiple sclerosis in the world. Thus, rising prevalence of these diseases in the countries such as U.S. and Canada, driving the growth of market.
  • The Asia Pacific region is anticipated to hold the considerable market share in the global immunomodulators market, owing to rising awareness about various immune disorders, In addition to this, favorable government regulations and increasing healthcare expenditure in the countries such as India and China, further propelling the growth of market in the Asia Pacific region. 

Competitive Analysis:

Developing and developed countries are offering greater opportunities and major players are continuously focused on new developments, strategic partnerships, acquisitions and venture capital investments to obtain high growth in the market.

In October 2019, Pandion Therapeutics, Inc. and Astellas Pharma Inc. announced the signing of a License and Collaboration Agreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of the pancreas.

In January 2020, KYORIN Holdings, Inc. today announced that it’s wholly owned subsidiary KYORIN Pharmaceutical Co., Ltd has entered into a collaboration and license agreement with aTyr Pharma, Inc. for Japan with regard to ATYR1923, aTyr’s novel immunomodulator to develop and commercialize ATYR1923 for interstitial lung diseases in Japan.

List of Key Market Players:

  • Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Abbott Laboratories
  • Johnson & Johnson
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Merck & Co.
  • Eli Lilly and Company
  • Pfizer Inc.
  • Biogen Inc.
  • Teva Pharmaceuticals
  • Pandion Therapeutics, Inc.
  • aTyr Pharma, Inc.

Key Target Audience

  • Healthcare Institutes
  • Drug Manufacturers
  • Pharmaceutical Companies
  • Government Authorities and R&D Institutions
  • World Health Organization
  • Food and Drug Administration
  • Consulting And Research Firms

Major factors covered in this report

  • Market Dynamics: Market Drivers and Restraints
  • Value-Chain: Supply and Demand Analysis
  • Cost and Price Structure Analysis
  • Competitive Analysis
  • Porter’s Five Forces Analysis

What will the report include?

  • Highlights of main global R&D activities and new technological developments
  • Estimation of the actual market size and revenue forecasts for global market
  • Description of the most relevant research and development activities related to Flying Taxi market places
  • Production of Flying Taxi, and review of application for Flying Taxi and assessment of emerging applications
  • Analyses of the global market trends, with data from 2020, estimates for 2021, and forecast through 2027
  • Review of current industry players, including manufacturers of Flying Taxi, technology developments, and future market participants

Some of the key questions addressed in the report were…

  • What were the market size in 2014 and the outlook from 2021 to 2027?
  • How much growth will the industry market experience between 2017 and 2027?
  • What are the important factors, constraints, and opportunities, and how they will affect market?
  • What are the key segments of the Flying Taxi market growth and why?
  • Who are the main participants and strategies they use to compete in the market?

Minds Insights is the foundation for data driven insights in various industry verticals using four key capabilities:

  • Qualitative Research
  • Quantitative Research
  • Strategy Building
  • Research Design

1          Introduction

  • Research Scope
  • Research Methodology and Assumptions
  • Market Segmentation
  • Definitions

2          Executive Summary

3          Market Overview

  • Market Segmentation & Scope
  • Value Chain Analysis
  • Supply Chain Analysis
  • Porter’s Five Forces Analysis
  • Regulatory Landscape
  • Macro-Economic Indicators
  • Cost Structure Analysis
  • Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
  • Market Evaluation

4          Impact of COVID-19 on the Market

5          Technological Analysis

  • Technology advances
  • Upcoming Technology Landscape

6          Competitive Analysis

  • Market Share Analysis
  • Potential Venture Analysis
  • Key Winning Strategies

7          Pricing Analysis

  • Regional Price Analysis
  • Raw Material Analysis

8          Immunomodulators Market, By Type Overview

  • IMMUNOSUPPRESSANTS
  • IMMUNOSTIMULANTS
  • OTHERS

9          Immunomodulators Market, By Applications Overview

  • ONCOLOGY
  • RESPIRATORY
  • OTHERS

10        Regional Overview

  • Overview
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
  • Rest of the World
  • Latin America
  • Middle East and Africa

11        Competitive Landscape (Manufacturers & Suppliers)

INTRODUCTION (Business Overview, Platform, Solutions & Services, Key Insights, Recent Developments, SWOT Analysis)

  • HOFFMANN-LA ROCHE LTD
  • AMGEN INC
  • ABBOTT LABORATORIES
  • JOHNSON & JOHNSON
  • NOVARTIS AG
  • BRISTOL-MYERS SQUIBB COMPANY
  • MERCK & CO
  • ELI LILLY AND COMPANY
  • PFIZER INC
  • BIOGEN INC

12        Conclusion & Recommendation

13        Analyst Review

14        Research Methodology

List of Figures

Fig.1    Product Picture of Immunomodulators

Fig.2    Global Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.3    Global Immunomodulators Market Absolute Revenue Opportunity, 2016 – 2026 (USD Million)

Fig.4    Global Immunomodulators Market Incremental Revenue Opportunity, 2020 – 2026 (USD Million)

Fig.5    COVID-19 Impacts on Immunomodulators Market

Fig.6    COVID-19 Impact on the Players

Fig.7    Business Strategies and Recommendations

Fig.8    Global Immunomodulators Market Share, By Type, 2019 & 2026 (USD Million)

Fig.9    Global IMMUNOSUPPRESSANTS Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.10  Global IMMUNOSTIMULANTS Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.11  Global OTHERS Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.12  Global Immunomodulators Market Share, By Application, 2019 & 2026 (USD Million)

Fig.13  Global ONCOLOGY Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.14  Global RESPIRATORY Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.15  Global OTHERS Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.16  Global Immunomodulators Market Share, by Region, 2019 & 2026 (USD Million)

Fig.17  North America Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.18  U.S. Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.19  Canada Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.20  Europe Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.21  Germany Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.22  France Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.23  U.K. Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.24  Italy Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.25  Spain Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.26  Portugal Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.27  Cyprus Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.28  Lithuania Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.29  Greece Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.30  Rest of Europe Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.31  Asia Pacific Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.32  China Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.33  Japan Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.34  India Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.35  South Korea Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.36  Rest of Asia Pacific Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.37  Latin America Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.38  Brazil Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.39  Mexico Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.40  Rest of Latin America Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.41  The Middle-East and Africa Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.42  GCC Countries Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.43  South Africa Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.44  Rest of Middle-East Africa Immunomodulators Market, 2016 – 2026 (USD Million)

Fig.45  Competitor Market Share – Revenue

Fig.46  HOFFMANN-LA ROCHE LTD Revenue and Growth Rate

Fig.47  HOFFMANN-LA ROCHE LTD Market Share

Fig.48 AMGEN INC Revenue and Growth Rate

Fig.49  AMGEN INC Market Share

Fig.50  ABBOTT LABORATORIES Revenue and Growth Rate

Fig.51  ABBOTT LABORATORIES Market Share

Fig.51  JOHNSON & JOHNSON Revenue and Growth Rate

Fig.52  JOHNSON & JOHNSON Market Share

Fig.53  NOVARTIS AG Revenue and Growth Rate

Fig.54  NOVARTIS AG Market Share

Fig.55  BRISTOL-MYERS SQUIBB COMPANY Revenue and Growth Rate

Fig.56  BRISTOL-MYERS SQUIBB COMPANY Market Share

Fig.57  MERCK & CO Revenue and Growth Rate

Fig.58  MERCK & CO Market Share

Fig.59  ELI LILLY AND COMPANY Revenue and Growth Rate

Fig.60  ELI LILLY AND COMPANY Market Share

Fig.61  PFIZER INC Revenue and Growth Rate

Fig.62  PFIZER INC Market Share

Fig.63  BIOGEN INC Revenue and Growth Rate

Fig.64  BIOGEN INC Market Share

Fig.65  Global Immunomodulators Market – Value Chain Analysis

Fig.66  Technology Roadmap and Timeline

Fig.67  Market Attractiveness Analysis – By Installation

Fig.68  Market Attractiveness Analysis – By Application

Fig.69  Market Attractiveness Analysis – By Region

 

List of Tables

Table 1 Global Immunomodulators Market, 2019 & 2026 (USD Million)

Table 2 Global Immunomodulators Market, By Type, 2016 – 2026 (USD Million)

Table 3 Global Immunomodulators Market, By Installation, 2016 – 2026 (USD Million)

Table 4 Global Immunomodulators Market, By Application, 2016 – 2026 (USD Million)

Table 5 Global Immunomodulators Market, by Region, 2016 – 2026 (USD Million)

Table 6 North America Immunomodulators Market, by Country, 2016 – 2026 (USD Million)

Table 7 North America Immunomodulators Market, By Type, 2016 – 2026 (USD Million)

Table 8 North America Immunomodulators Market, By Installation, 2016 – 2026 (USD Million)

Table 9 North America Immunomodulators Market, By Application, 2016 – 2026 (USD Million)

Table 10 Europe Immunomodulators Market, by Country, 2016 – 2026 (USD Million)

Table 11 Europe Immunomodulators Market, By Type, 2016 – 2026 (USD Million)

Table 12 Europe Immunomodulators Market, By Installation, 2016 – 2026 (USD Million)

Table 13 Europe Immunomodulators Market, By Application, 2016 – 2026 (USD Million)

Table 14 Asia Pacific Immunomodulators Market, by Country, 2016 – 2026 (USD Million)

Table 15 Asia Pacific Immunomodulators Market, By Type, 2016 – 2026 (USD Million)

Table 16 Asia Pacific Immunomodulators Market, By Installation, 2016 – 2026 (USD Million)

Table 17 Asia Pacific Immunomodulators Market, By Application, 2016 – 2026 (USD Million)

Table 18 Latin America Immunomodulators Market, by Country, 2016 – 2026 (USD Million)

Table 19 Latin America Immunomodulators Market, By Type, 2016 – 2026 (USD Million)

Table 20 Latin America Immunomodulators Market, By Installation, 2016 – 2026 (USD Million)

Table 21 Latin America Immunomodulators Market, By Application, 2016 – 2026 (USD Million)

Table 22 The Middle-East and Africa Immunomodulators Market, by Country, 2016 – 2026 (USD Million)

Table 23 The Middle-East and Africa Immunomodulators Market, By Type, 2016 – 2026 (USD Million)

Table 24 The Middle-East and Africa Immunomodulators Market, By Installation, 2016 – 2026 (USD Million)

Table 25 The Middle-East and Africa Immunomodulators Market, By Application, 2016 – 2026 (USD Million)

Table 26 Global Immunomodulators Market - Company Revenue Analysis, 2016 – 2019 (USD Million)

Table 27 Global Immunomodulators Market - Company Revenue Share Analysis, 2016 – 2019 (%)

Table 28 Acquisitions and Mergers

Table 29 Market Drivers – Impact Analysis

Table 30 Market Restraints

Table 31 Market Opportunities